The effects of rituximab on serum IgE and BAFF

Allergy, Asthma & Clinical Immunology

Angira Dasgupta²  Katherine Radford²  Donald M Arnold²  Lehana Thabane¹  Parameswaran Nair² 

[1] Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

[2] Department of Medicine, McMaster University, Hamilton, ON, Canada

关键词: Asthma;    BAFF;    Immunoglobulin E;    Rituximab;    Anti-CD20;   

Others  :  792127
DOI  :  10.1186/1710-1492-9-39

 received in 2013-07-24, accepted in 2013-08-27,  发布年份 2013

【 摘 要 】

Background

There are few treatment options for patients with severe atopic asthma. Antagonism of IgE is an effective strategy. We investigated, by utilizing serum samples from a clinical trial of Rituximab in patients with Idiopathic Thrombocytopenic Purpura, if B cell depletion would decrease serum IgE and therefore be a potential therapeutic option.

Findings

In a placebo-controlled randomized clinical trial of Rituximab, an anti-CD20 molecule, there were no significant differences in serum levels of IgE or BAFF levels between the two treatment groups at 3 or 6 months irrespective of the baseline serum IgE levels.

Conclusions

Since Rituximab did not significantly decrease serum IgE levels, this proof of concept study suggests that Rituximab may not be a useful treatment strategy for patients with severe IgE mediated disease.

【 授权许可】

   
2013 Dasgupta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stafford AN, Rider SH, Hopkin JM, Cookson WO, Monaco AP: A 2.8 Mb YAC contig in 11q12-q13 localizes candidate genes for atopy: Fc epsilon RI beta and CD20. Hum Mol Genet 1994, 3:779-785.
• [2]Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC: Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011, 26:2865-2871.
• [3]Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. Allergy Clin Immunol 2008, 121:122-128.
• [4]Kang JS, Yoon YD, Ahn JH, Kim SC, Kim KH, Kim HM, Moon EY: B cell-activating factor is a novel diagnosis parameter for asthma. Int Arch Allergy Immunol 2006, 141:181-188.
• [5]Jee HM, Choi BS, Kim KW, Sohn MH, Han MY, Kim KE: Increased B cell-activating factor (BAFF) level in the sputum of children with asthma. Korean J Pediatr 2010, 53:795-800.
• [6]Moon EY, Ryu SK: TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice. Exp Mol Med 2007, 39:343-352.
• [7]Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167. BioMed Central Full Text
• [8]Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, Liu Y, Cook RJ, McLeod A, Maceachern JA, Mangel J, Anderson D, Vickars L, Tinmouth A, Schuh AC, Kelton JG: A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patients with immune thrombocytopenia. Blood 2012, 119:1356-1362.
• [9]Medina F, Segundo C, Campos-Caro A, González-García I, Brieva JA: The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002, 99(6):2154-2161.
• [10]Dallos T, Krivosíková M, Chorazy-Massalska M, Warnawin E, Zánová E, Rudnicka W, et al.: BAFF from bone marrow-derived mesenchymal stromal cells of rheumatoid arthritis patients improves their B-cell viability-supporting properties. Folia Biol (Praha) 2009, 55(5):166-176.